1. Inicio
  2. Publicaciones
  3. Clinician Concepts of Cure in Adult Relapsed and Refractory Philadelphia-Negative B Cell Precursor Acute Lymphoblastic Leukemia: A Delphi Study

Clinician Concepts of Cure in Adult Relapsed and Refractory Philadelphia-Negative B Cell Precursor Acute Lymphoblastic Leukemia: A Delphi Study

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Bassan, R
  • Hoelzer, D
  • Thomas, X
  • Pavlu, J
  • McKendrick, J
  • Kudlac, A
  • Barlev, A
  • Barber, B
  • Cong, Z

Grupos

Abstract

Introduction: Despite the poor prognosis for adults with relapsed or refractory (RR) Philadelphia chromosome (Ph)-negative Bcell precursor acute lymphoblastic leukemia (ALL), long-term survival is possible and may even be considered as "cure". Methods: This study used a Delphi panel approach to explore concepts of cure in RR Ph-negative Bcell precursor ALL. Ten European experts in this disease area participated in a survey and face-to-face panel meeting. Results: Findings showed that clinicians conceptualize "cure" as a combination of three broad treatment outcomes that vary depending on the treatment stage: complete remission early in treatment (1-3 months) indicates initial success; eradicating cancer cells (minimal residual disease negative status) consolidates the early clinical response; leukemia-free survival is required in the long term. Conclusions: Although such terminology remains contested, clinicians would begin considering "cure" as early as 2 years provided the patient is off therapy, with most considering the term applicable by the third year.

Datos de la publicación

ISSN/ISSNe:
0741-238X, 1865-8652

ADVANCES IN THERAPY  SPRINGER

Tipo:
Article
Páginas:
870-879
PubMed:
30847777
Factor de Impacto:
0,979 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 5

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • B cell precursor acute lymphoblastic leukemia; Cure; Outcomes; Oncology; Refractory ALL; Relapsed ALL; Survival

Campos de Estudio

Cita

Compartir